With your own knowledge and the help of the following document:

Document 1 (Title: Cardiovascular and Renal Effects of the Renin-Angiotensin System): Angiotensin II represents a critical effector peptide mediating diverse physiological functions through multiple mechanisms affecting cardiovascular and renal homeostasis. Vascular effects feature prominently, with direct actions on vascular smooth muscle cells through binding to AT1 receptors activating phospholipase C signaling cascades that increase intracellular calcium, producing potent vasoconstriction independent of autonomic innervation. This direct vascular effect contributes significantly to blood pressure regulation and regional blood flow distribution. Additional cardiovascular effects include interactions with adrenergic neurotransmission, with angiotensin II enhancing catecholamine release from sympathetic nerve terminals while simultaneously reducing reuptake, thereby amplifying sympathetic nervous system activity. This mechanism provides indirect pressor effects complementing direct vascular actions. Neurohormonal regulation extends to multiple endocrine systems, with angiotensin II directly modulating aldosterone production through stimulation of adrenal zona glomerulosa cells independent of potassium or ACTH influences. This effect creates one arm of the classic renin-angiotensin-aldosterone system regulating sodium and volume homeostasis. The peptide further demonstrates complex interactions with serotonergic systems, though direct receptor interactions remain less established compared to other mechanistic pathways. Renal hemodynamic effects include preferential constriction of efferent versus afferent arterioles, thereby increasing glomerular filtration pressure while reducing renal blood flow. Contrary to common oversimplifications, angiotensin II exhibits inhibitory rather than stimulatory effects on renin release through short negative feedback loops, with elevated intrarenal angiotensin II concentrations suppressing juxtaglomerular apparatus renin production rather than enhancing it. These diverse mechanisms collectively position angiotensin II as a central regulatory peptide in cardiovascular physiology and pathophysiology across multiple organ systems.
Document 2 (Title: Pharmacological Management of Male Lower Urinary Tract Symptoms): Benign prostatic hyperplasia (BPH) represents a common condition affecting more than 50% of men over age 60, with progressive prevalence increasing with advancing age. The condition leads to bothersome lower urinary tract symptoms through both static (enlargement-related) and dynamic (tone-related) mechanisms of bladder outlet obstruction. Contemporary pharmacological management targets these distinct pathophysiological components with several medication classes. Alpha-1 adrenergic receptor antagonists act on the dynamic component by blocking sympathetic stimulation of smooth muscle within the prostate and bladder neck, thereby reducing urethral resistance without affecting prostate size. These agents are classified by receptor selectivity and pharmacokinetic properties. Tamsulosin demonstrates preferential affinity for alpha-1A receptors predominantly expressed in prostatic tissue, providing rapid symptom relief with minimal effects on vascular alpha-1B receptors, thereby reducing cardiovascular adverse effects such as orthostatic hypotension. This selective receptor profile makes tamsulosin particularly suitable for elderly patients and those with concurrent cardiovascular conditions. Alternative agents with different mechanisms include 5-alpha reductase inhibitors (finasteride, dutasteride), which address the static component by preventing conversion of testosterone to dihydrotestosterone, thereby reducing prostate volume over 3-6 months. Anticholinergic agents such as oxybutynin target bladder overactivity rather than outlet obstruction, but carry risk of urinary retention in men with significant BPH. Phosphodiesterase-5 inhibitors improve BPH symptoms through mechanisms involving nitric oxide pathways. Vasopressors like midodrine, indicated for orthostatic hypotension, have no role in BPH management and may worsen urinary symptoms through increased smooth muscle tone.
Document 3 (Title: Urinary Obstruction and Stasis   Kidney): The pressure within the renal pelvis is normally close to zero. When this pressure increases because of obstruction or reflux, the pelvis and calyces dilate. The degree of hydronephrosis that develops depends on the duration, degree, and site of the obstruction (Figure 12–4). The higher the obstruction, the greater the effect on the kidney. If the renal pelvis is entirely intrarenal and the obstruction is at the ureteropelvic junction, all the pressure will be exerted on the parenchyma (Klein et al., 2010). If the renal pelvis is extrarenal, only part of the pressure produced by a ureteropelvic stenosis is exerted on the parenchyma; this is because the extrarenal pelvis is embedded in fat and dilates more readily, thus "decompressing" the hydronephrotic left renal pelvis. Low density mass (P) in the left renal sinus had an attenuation value similar to that of water, suggesting the correct diagnosis. Unless intravenous contrast material is used, differentiation from a peripelvic cyst may be difficult. In the earlier stages, the renal pelvic musculature undergoes compensatory hypertrophy in its effort to force urine past the obstruction. Later, however, the muscle becomes stretched and atonic and decompensated. The progression of hydronephrotic atrophy is as follows (Chevalier, 2010; Rodriguez, 2004): 1. The earliest changes in the development of hydronephrosis are seen in the calyces. The end of a normal calyx is concave because of the papilla that projects into it; with increased intrapelvic pressure, the fornices become blunt and rounded. With persistence of increased intrapelvic pressure, the papilla becomes flattened, then convex (clubbed) as a result of compression enhanced by ischemic atrophy (Figure 12–5). The parenchyma between the calyces is affected to a lesser extent. The changes in the renal parenchyma are due to (a) compression atrophy from increased intrapelvic pressure (more accentuated with intrarenal pelves) and (b) ischemic atrophy from hemodynamic changes, mainly manifested in arcuate vessels that run at the base of the pyramids parallel to the kidney outline and are more vulnerable to compression between the renal capsule and the centrally increasing intrapelvic pressure. 2. This spotty atrophy is caused by the nature of the blood supply of the kidney. The arterioles are end arteries; therefore, ischemia is most marked in the areas farthest from the interlobular arteries. As the back pressure increases, hydronephrosis progresses, with the cells nearest the main arteries exhibiting the greatest resistance. 3. This increased pressure is transmitted up the tubules. The tubules become dilated, and their cells atrophy from ischemia. It should be pointed out that a few instances of dilated renal pelves and calyces are not due to the presence of obstruction. Rarely, the renal cavities are congenitally capacious and thus simulate hydronephrosis. More commonly, hydronephrosis may occur in childhood owing to the back pressure associated with vesicoureteral reflux. If the valvular incompetence resolves (and this is common), some degree of the hydronephrotic changes may persist. These persisting changes may cause the physician to suspect the presence of obstruction, which may lead to unnecessary surgery. A radioisotope renogram to assess ureteral drainage function can be performed to determine whether organic obstruction is present. 4. Only in unilateral hydronephrosis are the advanced stages of hydronephrotic atrophy seen. Eventually, the kidney is completely destroyed and appears as a thin walled sac filled with clear fluid (water and electrolytes) or pus (Figure 12–6).

Answer the following list question.
Question: Select the correct statement(s): Angiotensin II:
Options:
1. Exerts a direct effect on vascular smooth muscle
2. Exerts a direct action on serotonin receptors
3. Increases the release of catecholamines
4. Exerts a stimulating action on renin secretion
5. Modulates aldosterone secretion

Respond strictly in valid JSON format as shown below:
{"answer": ["1", "3"]} ← if options 1 and 3 are correct
Only output the JSON object. Do not include explanations, labels, markdown, or any other text.